key: cord-0829293-inyqoycp authors: Abi Zeid Daou, Christophe; Natout, Mohammad A.; El Hadi, Nadine title: Biphasic anaphylaxis after exposure to the first dose of Pfizer‐BioNTech COVID‐19 mRNA vaccine date: 2021-06-06 journal: J Med Virol DOI: 10.1002/jmv.27109 sha: cb43cf5d07a3a56c90204555fc9016fa165a202a doc_id: 829293 cord_uid: inyqoycp In the setting of a coronavirus disease 2019 (COVID‐19) global pandemic and increased disease burden, vaccination has become one of the major solutions. With the increase in vaccination numbers worldwide, it is important to stay vigilant to the potential side effects and life‐threatening complications of such vaccines. We report the case of a 30‐year‐old male with a biphasic allergic reaction post messenger (mRNA) Pfizer‐BioNTech COVID‐19 vaccination. Several reports of allergic reactions have been cited in the literature after the administration of the mRNA Pfizer‐BioNTech COVID‐19 vaccine. It is important to keep a high index of suspicion in severe anaphylactic cases as some patients may have a recurrence of symptoms after discharge. It is crucial to acknowledge the potential risk of anaphylaxis in select individuals and have the appropriate measures in place to deal with adverse events. In case of severe symptoms, the administration of epinephrine is advised to prevent the development of a delayed biphasic anaphylactic reaction. On December 11, 2020, the Food and Drug Administration (FDA) authorized the emergency use of the two-dose Pfizer-BioNTech COVID-19 vaccine. Globally, the latest vaccination rate is 6 469 833 doses per day, on average, with 41.7 million individuals having received the first dose of the vaccine. 1 As vaccination started in several countries, adverse events related to the vaccine were registered through the Vaccine Adverse Event Reporting System (VAERS). About 175 cases of severe allergic reactions were submitted for review thus far. 2 The Center for Disease Control (CDC) identified 21 case reports of anaphylaxis that met the Brighton Criteria. 3 We report the first case of biphasic anaphylaxis after exposure to the Pfizer-BioNTech COVID-19 vaccine. Pfizer-BioNTech vaccine with a full body and face diffuse maculopapular rash. His symptoms were associated with urticaria, diaphoresis, tachycardia, and tachypnea. The patient also reported dysphagia and palate pruritis. No dysphonia and no dyspnea. The otolaryngology team was contacted for an assessment of the airway. On physical examination, the patient was alert oriented and cooperative, and hemodynamically stable. He was breathing comfortably on room air, in no respiratory distress, and no stridor. There was no desaturation and facial asymmetry. No lip or eyelid swelling. On examination of the oral cavity, the uvula was midline, nonedematous, and the tongue was nonedematous as well. The patient had an episode of rash, pruritis, dyspnea, and diaphoresis at home. Symptoms resolved after the patient took prednisone 50 mg orally at home. He did not present to the ED due to the resolution of his symptoms. The patient reported back to work, however, he experienced sudden onset of rash followed by urticaria, diaphoresis, severe chills, and dysphagia. We were called again for an airway assessment. He took prednisone 50 mg PO as the rash appeared with no improvement. Intravenous access was secured. He was given diphenhydramine 25 mg iv, dexamethasone 8 mg iv, and hydrocortisone sodium succinate 250 mg iv once. The patient was then transferred to the ED. He was alert-oriented and cooperative, hemodynamically stable, however, using accessory abdominal muscles to breathe. No desaturation, SpO 2 was 100% but the patient was tachypneic without stridor. FFL during assessment showed an unremarkable exam with no evidence of edema or erythema along the upper airway. The patient was given in ED a second dose of diphenhydramine 25 mg iv once, dexamethasone 8 mg, and was kept for monitoring. On repeat assessment 3 h later, the patient was found to have mild swelling of the eyelids and lips with evidence of base of tongue edema and arytenoid erythema on FFL. The patient was still symptomatic with severe recurring pruritis, dyspnea, dysphagia, and sensation of throat closing up. The patient was given a third dose of diphenhydramine 25 mg iv, epinephrine IM 0.3 mg once, and was started on hydrocortisone sodium succinate 100 mg every 8 h. Repeat assessment and FFL after another 3 h showed resolution of all symptoms. The only remaining finding was the lagging arytenoid erythema without any evidence of airway compromise. The patient was hospitalized for observation. On Day 4 of events, the patient was in no acute distress with no recurrence of his symptoms. Edema had resolved with no audible stridor, no tachypnea, or chills. COVID-19 polymerase chain reaction was taken and found to be negative, to rule out any hyper-inflammatory reaction to the vaccine. Allergic reactions to vaccines have been widely described, for instance, the trivalent influenza vaccine has a postadministration reaction rate of 1.35 per million doses. 6 Confirmed allergic reactions to vaccines are not usually due to active ingredients but to the excipients added for the purpose of stabilizing and protecting the vaccine while eliciting a stronger immune response. 7 The Pfizer-BioNTech vaccine has been formulated with polyethylene glycol (PEG) for the purpose of stabilizing the lipid particle containing the virus mRNA. PEG has never been used in vaccines previously, however, there is cross-reactivity with polysorbate used in multiple vaccines (such as Influenza, Hepatitis B, etc.) and drugs (Amiodarone and many anti-neoplastic medications). It was hypothesized that previous exposure to polysorbate might explain the allergic reaction to the administration of the Pfizer-BioNTech COVID-19 mRNA vaccine. 8 This cross-reactivity between PEG and polysorbate is proportional to PEG molecular weight, with PEG-IgG exhibiting a higher affinity to PEG molecules with molecular weights above 1000. 8 To note that our patient had taken the Influenza vaccine earlier that year. Of the 21 identified cases of anaphylaxis to the COVID-19 Pfizer-BioNTech vaccine from the CDC, the most common symptoms at presentation were urticaria, angioedema, rash, and sensation of throat closure. 3 Similarly, the Moderna COVID-19 vaccine is an mRNA vaccine as well and has been associated with allergic side effects after administration. The literature cites 10 cases of anaphylaxis after administration of the first 4 041 396 doses at an estimated rate of 2.5 cases per million doses administered. 9 No reports of biphasic anaphylaxis after any of the two mRNA COVID-19 vaccines were encountered during our literature review. Biphasic anaphylaxis is characterized by an initial onset of allergy symptoms with subsequent complete resolution. This symptom-free period is then followed by subsequent recurrence of symptoms without re-exposure to culprit allergen. 10 The duration of the symptom-free period separating both reactions vary between 1 and 78 h. 11 The pathogenesis of biphasic anaphylaxis is still not clear due to the rarity of this entity. Some suggest that the late synthesis of Platelet Activating Factor (PAF) was responsible for the second delayed reaction. PAF is already established to play an important role in murine anaphylaxis pathogenesis and is upregulated by TNF-alpha expression. This theory is further supported by the inhibition of the late-phase response by TNF-alpha inhibition. 12 Other studies suggest that the delayed phase reaction is more likely due to uneven antigen absorption. This polyphasic absorption causes the body to be exposed and react to the allergen multiple times and stimulating biphasic anaphylaxis. 13 This is mostly true of orally absorbed allergens, however, intramuscular route administration can result in biphasic absorption if precipitation occurs at the injection site. 14 Possible risk factors for the development of a biphasic reaction include severe presenting symptoms such as hypotension 15 and inadequate or delayed administration of epinephrine during the initial encounter. 16 This might explain why our patient developed a biphasic allergic reaction, as he did not receive epinephrine on Day 1. Glucocorticoids and antihistamines have not been shown to significantly reduce the incidence of symptom recurrence in these patients. 16, 17 4 | CONCLUSION It is highly important to differentiate allergic from nonallergic reactions following vaccine administration. In that light, it is crucial to acknowledge the potential risk of anaphylaxis in select individuals and have the appropriate measures in place to deal with adverse events. In case of anaphylaxis to Pfizer-BioNTech COVID-19mRNA vaccine, it is essential to provide adequate symptomatic and diagnostic management. In case of severe symptoms, the administration of epinephrine is advised to prevent the development of a delayed biphasic anaphylactic reaction. More Than 193 Million Shots Given: COVID-19 Tracker Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -United States Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine Vaccine allergies mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach Risk of anaphylaxis after vaccination in children and adults Immunemediated adverse reactions to vaccines Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized CDC COVID-19 Response Team. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna Biphasic anaphylactic reactions Biphasic anaphylaxis: a review of the literature and implications for emergency management Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis Biphasic anaphylactic reactions in pediatrics Absorption of oral and intramuscular chlordiazepoxide Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis Biphasic reactions in emergency department anaphylaxis patients: a prospective cohort study Do corticosteroids prevent biphasic anaphylaxis? The authors declare that there are no conflicts of interest. https://orcid.org/0000-0001-9706-0066